Insulet shares are currently trading at their lowest valuation in a decade, presenting a notable opportunity for long-term investors. A recent operational stumble regarding new patient onboarding in the U.S. triggered a sharp sell-off, with the stock falling roughly 20% on August 5. While the company revised its full-year revenue outlook, the underlying fundamentals remain strong. Revenue growth reached 23.5% in the second quarter, outperforming expectations. The core issue is not a decline in demand but rather a retention hurdle for new Type 2 diabetes patients.
Fixing the Retention Gap
Insulet is struggling to keep Type 2 patients engaged during their first 90 days of treatment. Management acknowledges this friction and is responding with enhanced support programs, primary care physician involvement, and new sales incentives. CEO Ashley McEvoy noted that while demand remains high, the company failed to catch these drop-offs early enough. International markets continue to perform well, with growth rates for the region rising to 32%. Total adjusted earnings per share growth for the full year is projected to exceed 30%.
The GLP-1 Misconception
Investor panic surrounding GLP-1 weight loss drugs has weighed on the stock for months. The market initially feared these treatments would replace the need for insulin delivery systems. Actual data suggests the opposite. GLP-1 drugs often serve as a bridge that brings more patients into active treatment, many of whom ultimately require insulin therapy. These drugs do not remove the necessity of pumps for patients with insulin-dependent diabetes. Insulet’s Omnipod remains a core tool for long-term management, and the current market discount ignores this structural tailwind.
Valuation and Future Outlook
Trading at roughly 21x forward earnings, Insulet sits well below its historical range of 40x to 60x. A conservative re-rating to 28x points toward a potential price target near $196. This target does not require the company to reclaim its peak valuation, only a moderate correction from the current trough. Investors will look to the third-quarter retention data and the upcoming 2027 long-range outlook for proof that the onboarding issues are resolved. The company holds a distinct competitive edge through its tubeless design and pharmacy-based distribution model, shielding it from the logistics complexity faced by rivals. While risks related to reimbursement coverage persist, the current price reflects a level of pessimism that the firm's balance sheet and growth trajectory do not justify.